Beaukev Pharma International Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 8 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.08 M
- Revenue Growth -62.17%
- Profit Growth -16.70%
- Ebitda -55.14%
- Net Worth 120.42%
- Total Assets -29.83%
About Beaukev Pharma International
Beaukev Pharma International Private Limited (BPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 February 2016 (Nine years 8 days old ). Its registered office is in Thane, Maharashtra.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.08 M.
Kevin Trott and Mary Trott serve as directors at the Company.
Company Details
- Location Thane, Maharashtra
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909MH2016PTC273076
- Company No.
273076
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Feb 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Beaukev Pharma International?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mary Trott  | Director | 12-Feb-2016 | Current |
| Kevin Trott | Director | 12-Feb-2016 | Current |
Financial Performance of Beaukev Pharma International.
Beaukev Pharma International Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 62.17% decrease. The company also saw a substantial fall in profitability, with a 16.7% decrease in profit. The company's net worth Soared by an impressive increase of 120.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Beaukev Pharma International?
In 2022, Beaukev Pharma International had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Global Studyhub Opc Private LimitedMary Trott is a mutual person
Charges (Loans)
₹3.08 M
₹0
Charges Breakdown by Lending Institutions
- Yes Bank Limited : 0.31 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Aug 2023 | Yes Bank Limited | ₹3.08 M | Open |
How Many Employees Work at Beaukev Pharma International?
Unlock and access historical data on people associated with Beaukev Pharma International, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Beaukev Pharma International, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Beaukev Pharma International's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.